[HTML][HTML] Mechanisms of resistance in castration-resistant prostate cancer (CRPC)
Despite advances in prostate cancer diagnosis and management, morbidity from prostate
cancer remains high. Approximately 20% of men present with advanced or metastatic …
cancer remains high. Approximately 20% of men present with advanced or metastatic …
Nuclear receptor crosstalk—defining the mechanisms for therapeutic innovation
K De Bosscher, SJ Desmet, D Clarisse… - Nature Reviews …, 2020 - nature.com
Nuclear receptor crosstalk can be defined as the interplay between different nuclear
receptors or between their overlap** signalling pathways. A subset of nuclear receptors …
receptors or between their overlap** signalling pathways. A subset of nuclear receptors …
Histone methyltransferase DOT1L coordinates AR and MYC stability in prostate cancer
The histone methyltransferase DOT1L methylates lysine 79 (K79) on histone H3 and is
involved in Mixed Lineage Leukemia (MLL) fusion leukemogenesis; however, its role in …
involved in Mixed Lineage Leukemia (MLL) fusion leukemogenesis; however, its role in …
Nuclear receptors: recent drug discovery for cancer therapies
Nuclear receptors (NRs) are transcription factors actively involved in many aspects of human
physiology and pathology, serving as sensors of stimuli, master regulators of downstream …
physiology and pathology, serving as sensors of stimuli, master regulators of downstream …
Inhibition of the Wnt/β-catenin pathway overcomes resistance to enzalutamide in castration-resistant prostate cancer
Enzalutamide is a second-generation nonsteroidal antiandrogen clinically approved for the
treatment of castration-resistant prostate cancer (CRPC), yet resistance to endocrine therapy …
treatment of castration-resistant prostate cancer (CRPC), yet resistance to endocrine therapy …
p300/CBP inhibition enhances the efficacy of programmed death-ligand 1 blockade treatment in prostate cancer
Blockade of programmed death-ligand 1 (PD-L1) by therapeutic antibodies has shown to be
a promising strategy in cancer therapy, yet clinical response in many types of cancer …
a promising strategy in cancer therapy, yet clinical response in many types of cancer …
Activation of MAPK signaling by CXCR7 leads to enzalutamide resistance in prostate cancer
Castration-resistant prostate cancer (CRPC) that has developed resistance to the new-
generation androgen receptor (AR) antagonist enzalutamide is a lethal disease …
generation androgen receptor (AR) antagonist enzalutamide is a lethal disease …
Androgen receptor-dependent and-independent mechanisms driving prostate cancer progression: Opportunities for therapeutic targeting from multiple angles
DT Hoang, KA Iczkowski, D Kilari, W See… - …, 2016 - pmc.ncbi.nlm.nih.gov
Despite aggressive treatment for localized cancer, prostate cancer (PC) remains a leading
cause of cancer-related death for American men due to a subset of patients progressing to …
cause of cancer-related death for American men due to a subset of patients progressing to …
Inhibition of cholesterol biosynthesis overcomes enzalutamide resistance in castration-resistant prostate cancer (CRPC)
Enzalutamide, a nonsteroidal second-generation antiandrogen, has been recently approved
for the management of castration-resistant prostate cancer (CRPC). Although patients can …
for the management of castration-resistant prostate cancer (CRPC). Although patients can …
Cancer-associated fibroblasts promote prostate tumor growth and progression through upregulation of cholesterol and steroid biosynthesis
H Neuwirt, J Bouchal, G Kharaishvili, C Ploner… - Cell Communication and …, 2020 - Springer
Background Androgen receptor targeted therapies have emerged as an effective tool to
manage advanced prostate cancer (PCa). Nevertheless, frequent occurrence of therapy …
manage advanced prostate cancer (PCa). Nevertheless, frequent occurrence of therapy …